scispace - formally typeset
X

Xiang Bo Wan

Researcher at Sun Yat-sen University

Publications -  28
Citations -  5601

Xiang Bo Wan is an academic researcher from Sun Yat-sen University. The author has contributed to research in topics: Nasopharyngeal neoplasm & Nasopharyngeal carcinoma. The author has an hindex of 18, co-authored 25 publications receiving 4576 citations. Previous affiliations of Xiang Bo Wan include Dalian Medical University.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Elevated Beclin 1 expression is correlated with HIF-1alpha in predicting poor prognosis of nasopharyngeal carcinoma.

TL;DR: It is demonstrated that high autophagic Beclin 1 expression was an inferior prognostic marker for NPC cells surviving from chemoradiotherapy, suggesting a novel therapeutic molecular target for NPC.
Journal ArticleDOI

Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia.

TL;DR: It is found that expression of Aur-A was markedly elevated in bone marrow mononuclear cells obtained from a significant portion of de novo acute myeloid leukemia (AML) patients, and VX-680 enhanced the cytotoxic effect of the chemotherapeutic agent etoposide (VP16) on AML cells.
Journal ArticleDOI

Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells.

TL;DR: It is shown that Aur-A kinase, a negative prognostic marker, promotes migration and reduces radiosensitivity in laryngeal cancer cells.
Journal ArticleDOI

Endoscopic nasopharyngectomy for locally recurrent nasopharyngeal carcinoma.

TL;DR: An innovative, minimally invasive, oncological, endoscopic nasopharyngectomy for locally recurrent nasopharygeal carcinoma is introduced.